Advanced Accelerator Applications   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Saint Denis Pouilly France (2002)
Status: Acquired by Novartis (2018)

Organization Overview

First Clinical Trial
2011
NCT01379677
First Marketed Drug
2016
gallium-68-dotatate (netspot)
First NDA Approval
2016
gallium-68-dotatate (netspot)
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Advanced Accelerator Applications | Advanced Accelerator Applications SA

Indications

Approved Indications


 

Neuroendocrine Tumors

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoid Tumor (Phase 3)

Carcinoma (Phase 2)

Carcinoma, Islet Cell (Phase 2)

Carcinoma, Neuroendocrine (Phase 2)

Cardiomyopathies (Phase 2)

Cardiotoxicity (Phase 2)

Carotid Body Tumor (Phase 2)

Carotid Stenosis (Phase 2)

Coronary Artery Disease (Phase 3)

Coronary Disease (Phase 3)

Hypersensitivity (Phase 2)

Lung Neoplasms (Phase 2)

Mesothelioma (Phase 1)

Myocardial Ischemia (Phase 3)

Neoplasms (Phase 3)

Neuroblastoma (Phase 2)

Neuroendocrine Tumors (Phase 3)

Pancreatic Neoplasms (Phase 2)

Paraganglioma (Phase 2)

Pheochromocytoma (Phase 2)

Prostatic Neoplasms (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Spondylarthritis (Phase 2)

Spondylitis (Phase 2)

Spondylitis, Ankylosing (Phase 2)

Thymoma (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 30
  • # of Trial APIs: 23